Clinical Trials · NCT01419197
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 602
- Start date
- Sep 2011
- Locations
- 184 sites, 22 countries
- Primary endpoint
- Progression-free Survival